logo
Share SHARE
FONT-SIZE Plus   Neg

Salix, Progenics Announce FDA Extension Of RELISTOR SNDA Goal Date To July 27

Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration, or FDA, has extended the Prescription Drug User Fee Act goal date for the Agency's review of the Supplemental New Drug Application, or sNDA, for RELISTOR (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

The FDA has notified Salix that it requires additional time for a full review of the submission and has extended the April 27, 2012 goal date by the standard extension period of three months. The extended user fee goal date is July 27, 2012. The extension requested no additional studies.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dutch consumer electronics giant Philips Electronics NV Wednesday announced a definitive merger agreement to buy Spectranetics Corp., a vascular intervention and lead management solutions provider. Under the deal, Philips will commence a tender offer to buy Spectranetics for $38.50 per share, to be paid in cash upon completion. The implied enterprise value is approximately 1.9 billion euros. Samsung Electronics Co. is reviving its Galaxy Note 7 premium smartphone, which was recalled last year over faulty battery issues. A refurbished version of the smartphone with different components under the name Galaxy Note 7 Fandom Edition or FE will be coming to retailers' shelves on July 7, reports said. A massive cyberattack has hit Europe on Tuesday, spreading to U.S. and Asia, affecting businesses and government systems with ransom demands. The new ransomware attack, in a possible reprise of a widespread WannaCry assault in May, is said to be caused by the virus linked to malware called Petrwrap or Petya. The affected users are told to pay $300 in cryptocurrency per infected computer...
comments powered by Disqus
Follow RTT